Recce Pharmaceuticals Ltd

ASX:RCE Stock Report

Market Cap: AU$112.3m

Recce Pharmaceuticals Future Growth

Future criteria checks 5/6

Recce Pharmaceuticals is forecast to grow earnings and revenue by 68.7% and 92.7% per annum respectively while EPS is expected to grow by 70.6% per annum.

Key information

68.7%

Earnings growth rate

70.57%

EPS growth rate

Pharmaceuticals earnings growth45.7%
Revenue growth rate92.7%
Future return on equityn/a
Analyst coverage

Low

Last updated23 Jul 2026

Recent future growth updates

Recent updates

Analysis Article • Nov 01

We Think Shareholders Are Less Likely To Approve A Pay Rise For Recce Pharmaceuticals Ltd's (ASX:RCE) CEO For Now

Key Insights Recce Pharmaceuticals' Annual General Meeting to take place on 7th of November Total pay for CEO James...
Analysis Article • Feb 13

Here's Why We're Watching Recce Pharmaceuticals' (ASX:RCE) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jul 28

We're Hopeful That Recce Pharmaceuticals (ASX:RCE) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Dec 07

Recce Pharmaceuticals (ASX:RCE) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Earnings and Revenue Growth Forecasts

ASX:RCE - Analysts future estimates and past financials data (AUD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/2028543333331
6/30/202712-25-25-32
6/30/20268-18-15-182
12/31/20251-30-23-23N/A
9/30/20254-26-22-22N/A
6/30/20258-21-20-20N/A
3/31/20259-20-17-17N/A
12/31/202410-18-13-13N/A
9/30/20247-18-13-13N/A
6/30/20245-18-13-13N/A
3/31/20246-14-11-11N/A
12/31/20237-11-9-9N/A
9/30/20236-12-11-11N/A
6/30/20234-13-13-13N/A
3/31/20234-14-14-14N/A
12/31/20223-15-15-14N/A
9/30/20223-13-12-12N/A
6/30/20223-11-9-9N/A
3/31/20222-10-8-8N/A
12/31/20211-8-7-7N/A
9/30/20211-11-8-8N/A
6/30/20212-14-8-8N/A
3/31/20211-13-8-8N/A
12/31/20201-13-8-8N/A
9/30/20201-9-6-6N/A
6/30/20201-4-4-4N/A
3/31/20201-4-3-3N/A
12/31/20191-3-3-3N/A
9/30/20191-3N/A-3N/A
6/30/20191-3N/A-3N/A
3/31/20191-2N/A-2N/A
12/31/20182-2N/A-2N/A
9/30/20181-2N/A-2N/A
6/30/20181-2N/A-2N/A
3/31/20181-2N/A-2N/A
12/31/20171-3N/A-2N/A
9/30/20170-3N/A-2N/A
6/30/20170-3N/A-2N/A
3/31/20170-3N/A-2N/A
12/31/20160-2N/A-2N/A
9/30/20160-4N/A-2N/A
6/30/20160-5N/A-2N/A
3/31/20160-5N/A-1N/A
12/31/20150-4N/A-1N/A
9/30/20150-2N/A0N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RCE is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.6%).

Earnings vs Market: RCE is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: RCE is expected to become profitable in the next 3 years.

Revenue vs Market: RCE's revenue (92.7% per year) is forecast to grow faster than the Australian market (5.7% per year).

High Growth Revenue: RCE's revenue (92.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if RCE's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/27 07:53
End of Day Share Price 2026/07/27 00:00
Earnings2025/12/31
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Recce Pharmaceuticals Ltd is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jyoti PrakashEdison Investment Research
Chris KallosMST Financial Services Pty Limited
Rita FungMST Financial Services Pty Limited